1/13
05:31 pm
nbp
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
1/13
05:31 pm
nbp
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
1/8
07:30 am
nbp
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Medium
Report
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
1/6
07:22 am
nbp
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer [Yahoo! Finance]
High
Report
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer [Yahoo! Finance]
1/6
07:00 am
nbp
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
High
Report
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
12/30
07:11 am
nbp
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 [Yahoo! Finance]
Low
Report
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 [Yahoo! Finance]
12/30
07:00 am
nbp
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
Low
Report
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
12/14
11:40 pm
nbp
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
Low
Report
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
12/11
01:23 am
nbp
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO [Yahoo! Finance]
Medium
Report
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO [Yahoo! Finance]
12/11
01:12 am
nbp
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Medium
Report
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
12/10
04:30 pm
nbp
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Medium
Report
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
12/4
07:34 am
nbp
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Low
Report
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
12/3
07:30 pm
nbp
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Medium
Report
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
11/21
12:46 am
nbp
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Medium
Report
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
11/20
08:00 pm
nbp
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Medium
Report
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
10/30
04:15 am
nbp
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Medium
Report
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
10/29
06:27 pm
nbp
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Low
Report
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries